Next-generation sequencing (NGS) continues to evolve yet challenges exist. We are developing in vitro diagnostics (IVDs) and Personalized Cancer Monitoring (PCM™) for solid tumor biomarker identification.
We are developing a new solid tumor IVD designed to identify actionable genomic alterations in tissue and blood samples that is intended for use as a companion diagnostic.
The panel has received two Breakthrough Device Designations from the U.S. FDA.
We are developing Personalized Cancer Monitoring (PCM™) panels that are patient-specific, highly sensitive and minimally invasive liquid biopsy tests intended for monitoring early-stage cancer treatment and recurrence.